The potential of CAR T therapy for relapsed or refractory pediatric and young adult B-cell ALL

Recent advancements in immunooncology have resulted in the generation of novel therapies such as chimeric antigen receptor (CAR) T cells, which have revolutionized the treatment of pediatric patients with relapsed or refractory B-cell acute lymphoblastic leukemia. The journey of tisagenlecleucel (fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Forsberg, Matthew H, Das, Amritava, Saha, Krishanu, Capitini, Christian M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6130274/
https://www.ncbi.nlm.nih.gov/pubmed/30233192
http://dx.doi.org/10.2147/TCRM.S146309
_version_ 1783353909616574464
author Forsberg, Matthew H
Das, Amritava
Saha, Krishanu
Capitini, Christian M
author_facet Forsberg, Matthew H
Das, Amritava
Saha, Krishanu
Capitini, Christian M
author_sort Forsberg, Matthew H
collection PubMed
description Recent advancements in immunooncology have resulted in the generation of novel therapies such as chimeric antigen receptor (CAR) T cells, which have revolutionized the treatment of pediatric patients with relapsed or refractory B-cell acute lymphoblastic leukemia. The journey of tisagenlecleucel (formerly CTL019) from early preclinical success to the US Food and Drug Administration approval is summarized in this review. Strategies that are currently being investigated to improve the efficacy and safety profile of CAR T-cells are also explored, as well as the factors contributing to the present state of patient access to CAR T therapy.
format Online
Article
Text
id pubmed-6130274
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-61302742018-09-19 The potential of CAR T therapy for relapsed or refractory pediatric and young adult B-cell ALL Forsberg, Matthew H Das, Amritava Saha, Krishanu Capitini, Christian M Ther Clin Risk Manag Review Recent advancements in immunooncology have resulted in the generation of novel therapies such as chimeric antigen receptor (CAR) T cells, which have revolutionized the treatment of pediatric patients with relapsed or refractory B-cell acute lymphoblastic leukemia. The journey of tisagenlecleucel (formerly CTL019) from early preclinical success to the US Food and Drug Administration approval is summarized in this review. Strategies that are currently being investigated to improve the efficacy and safety profile of CAR T-cells are also explored, as well as the factors contributing to the present state of patient access to CAR T therapy. Dove Medical Press 2018-09-03 /pmc/articles/PMC6130274/ /pubmed/30233192 http://dx.doi.org/10.2147/TCRM.S146309 Text en © 2018 Forsberg et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Review
Forsberg, Matthew H
Das, Amritava
Saha, Krishanu
Capitini, Christian M
The potential of CAR T therapy for relapsed or refractory pediatric and young adult B-cell ALL
title The potential of CAR T therapy for relapsed or refractory pediatric and young adult B-cell ALL
title_full The potential of CAR T therapy for relapsed or refractory pediatric and young adult B-cell ALL
title_fullStr The potential of CAR T therapy for relapsed or refractory pediatric and young adult B-cell ALL
title_full_unstemmed The potential of CAR T therapy for relapsed or refractory pediatric and young adult B-cell ALL
title_short The potential of CAR T therapy for relapsed or refractory pediatric and young adult B-cell ALL
title_sort potential of car t therapy for relapsed or refractory pediatric and young adult b-cell all
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6130274/
https://www.ncbi.nlm.nih.gov/pubmed/30233192
http://dx.doi.org/10.2147/TCRM.S146309
work_keys_str_mv AT forsbergmatthewh thepotentialofcarttherapyforrelapsedorrefractorypediatricandyoungadultbcellall
AT dasamritava thepotentialofcarttherapyforrelapsedorrefractorypediatricandyoungadultbcellall
AT sahakrishanu thepotentialofcarttherapyforrelapsedorrefractorypediatricandyoungadultbcellall
AT capitinichristianm thepotentialofcarttherapyforrelapsedorrefractorypediatricandyoungadultbcellall
AT forsbergmatthewh potentialofcarttherapyforrelapsedorrefractorypediatricandyoungadultbcellall
AT dasamritava potentialofcarttherapyforrelapsedorrefractorypediatricandyoungadultbcellall
AT sahakrishanu potentialofcarttherapyforrelapsedorrefractorypediatricandyoungadultbcellall
AT capitinichristianm potentialofcarttherapyforrelapsedorrefractorypediatricandyoungadultbcellall

Ejemplares similares